Topical administration of GLP-1 receptor agonists prevents retinal neurodegeneration in experimental diabetes

Diabetes

Volumn 65, Issue 1, 2016, Pages 172-187

  Hernández, Cristina ^a,b   Bogdanov, Patricia ^a,b   Corraliza, Lidia ^a,b   García Ramírez, Marta ^a,b   Solà Adell, Cristina ^a,b   Arranz, José A ^c   Arroba, Ana I ^b,d   Valverde, Angela M ^b,d   Simó, Rafael ^a,b  

^a UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^b INSTITUTO DE SALUD CARLOS III   (Spain)

^c HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^d UNIVERSIDAD AUTÓNOMA DE MADRID   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

EXENDIN 4; EYE DROPS; GLUCAGON LIKE PEPTIDE 1 RECEPTOR; GLUCOSE; GLUTAMIC ACID; INTERLEUKIN 1BETA; LIRAGLUTIDE; LIXISENATIDE; PLACEBO; VASCULOTROPIN; GLIAL FIBRILLARY ACIDIC PROTEIN; GLUCAGON LIKE PEPTIDE 1; NEUROPROTECTIVE AGENT; PEPTIDE; VENOM; ZP10A PEPTIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CELL ACTIVATION; CLINICAL ARTICLE; CONTROLLED STUDY; DB/DB MOUSE; DIABETIC RETINOPATHY; DOWN REGULATION; DRUG MECHANISM; ELECTRORETINOGRAPHY; EYE PROTECTION; FEMALE; GLIA CELL; GLUCOSE BLOOD LEVEL; HUMAN; HUMAN TISSUE; MALE; MOUSE; NERVE DEGENERATION; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; RETINA DEGENERATION; RETINAL NEURODEGENERATION; SIGNAL TRANSDUCTION; SINGLE DRUG DOSE; SURVIVAL; SYSTEMIC THERAPY; TOPICAL TREATMENT; WESTERN BLOTTING; AGED; AGONISTS; ANIMAL; COMPLICATION; DRUG EFFECTS; EXPERIMENTAL DIABETES MELLITUS; GENETICS; IMMUNOHISTOCHEMISTRY; INTRAOCULAR DRUG ADMINISTRATION; METABOLISM; MIDDLE AGED; NON INSULIN DEPENDENT DIABETES MELLITUS; PATHOLOGY; REAL TIME POLYMERASE CHAIN REACTION; RETINA; RETINA NERVE CELL;

ADMINISTRATION, OPHTHALMIC; AGED; ANIMALS; APOPTOSIS; BLOTTING, WESTERN; DIABETES MELLITUS, EXPERIMENTAL; DIABETES MELLITUS, TYPE 2; DIABETIC RETINOPATHY; ELECTRORETINOGRAPHY; FEMALE; GLIAL FIBRILLARY ACIDIC PROTEIN; GLUCAGON-LIKE PEPTIDE 1; GLUCAGON-LIKE PEPTIDE-1 RECEPTOR; HUMANS; IMMUNOHISTOCHEMISTRY; LIRAGLUTIDE; MALE; MICE; MIDDLE AGED; NEUROPROTECTIVE AGENTS; PEPTIDES; REAL-TIME POLYMERASE CHAIN REACTION; RETINA; RETINAL NEURONS; VENOMS;

EID: 84962147366     PISSN: 00121797     EISSN: 1939327X     Source Type: Journal    
DOI: 10.2337/db15-0443     Document Type: Article

References (45)

1. Carrasco E, Hernández C, Miralles A, Huguet P, Farrés J, Simó R. Lower somatostatin expression is an early event in diabetic retinopathy and is associated with retinal neurodegeneration. Diabetes Care 2007;30:2902-2908
2. Carrasco E, Hernández C, de Torres I, Farrés J, Simó R. Lowered cortistatin expression is an early event in the human diabetic retina and is associated with apoptosis and glial activation. Mol Vis 2008;14:1496-1502
3. Barber AJ, Lieth E, Khin SA, Antonetti DA, Buchanan AG, Gardner TW. Neural apoptosis in the retina during experimental and human diabetes. Early onset and effect of insulin. J Clin Invest 1998;102:783-791
4. Barber AJ. A new view of diabetic retinopathy: a neurodegenerative disease of the eye. Prog Neuropsychopharmacol Biol Psychiatry 2003;27:283-290
5. Simó R, Hernández C; European Consortium for the Early Treatment of Diabetic Retinopathy (EUROCONDOR). Neurodegeneration is an early event in diabetic retinopathy: therapeutic implications. Br J Ophthalmol 2012;96:1285-1290
6. Roy MS, Gunkel RD, Podgor MJ. Color vision defects in early diabetic ret-inopathy. Arch Ophthalmol 1986;104:225-228
7. Di Leo MA, Falsini B, Caputo S, Ghirlanda G, Porciatti V, Greco AV. Spatial frequency-selective losses with pattern electroretinogram in type 1 (insulin-dependent) diabetic patients without retinopathy. Diabetologia 1990;33:726-730
8. Di Leo MA, Caputo S, Falsini B, Porciatti V, Greco AV, Ghirlanda G. Presence and further development of retinal dysfunction after 3-year follow up in IDDM patients without angiographically documented vasculopathy. Diabetologia 1994; 37:911-916
9. Antonetti DA, Klein R, Gardner TW. Diabetic retinopathy. N Engl J Med 2012; 366:1227-1239
10. Simó R, Hernández C; European Consortium for the Early Treatment of Diabetic Retinopathy (EUROCONDOR). Neurodegeneration in the diabetic eye: new insights and therapeutic perspectives. Trends Endocrinol Metab 2014;25:23-33
11. Bogdanov P, Corraliza L, Villena JA, et al. The db/db mouse: a useful model for the study of diabetic retinal neurodegeneration. PLoS One 2014;9:e97302
12. During MJ, Cao L, Zuzga DS, et al. Glucagon-like peptide-1 receptor is involved in learning and neuroprotection. Nat Med 2003;9:1173-1179
13. Holst JJ, Burcelin R, Nathanson E. Neuroprotective properties of GLP-1: theoretical and practical applications. Curr Med Res Opin 2011;27:547-558
14. Hölscher C. Potential role of glucagon-like peptide-1 (GLP-1) in neuroprotection. CNS Drugs 2012;26:871-882
15. Zhang Y, Zhang J, Wang Q, et al. Intravitreal injection of exendin-4 analogue protects retinal cells in early diabetic rats. Invest Ophthalmol Vis Sci 2011;52: 278-285
16. Fan Y, Liu K, Wang Q, Ruan Y, Zhang Y, Ye W. Exendin-4 protects retinal cells from early diabetes in Goto-Kakizaki rats by increasing the Bcl-2/Bax and Bcl-xL/Bax ratios and reducing reactive gliosis. Mol Vis 2014;20:1557-1568
17. Lovshin JA, Huang Q, Seaberg R, Brubaker PL, Drucker DJ. Extra-hypothalamic expression of the glucagon-like peptide-2 receptor is coupled to reduction of glutamate-induced cell death in cultured hippocampal cells. Endocrinology 2004;145:3495-3506
18. Chen S, An FM, Yin L, et al. Glucagon-like peptide-1 protects hippocampal neurons against advanced glycation end product-induced tau hyperphosphorylation. Neuroscience 2014;256:137-146
19. Zhang Y, Wang Q, Zhang J, Lei X, Xu GT, Ye W. Protection of exendin-4 analogue in early experimental diabetic retinopathy. Graefes Arch Clin Exp Ophthalmol 2009;247:699-706
20. Fisher ME, Clelland AK, Bain A, et al. Integrating technologies for comparing 3D gene expression domains in the developing chick limb. Dev Biol 2008;317: 13-23
21. Puddu A, Sanguineti R, Montecucco F, Viviani GL. Retinal pigment epithelial cells express a functional receptor for glucagon-like peptide-1 (GLP-1). Mediators Inflamm 2013;2013:975032
22. Marmor MF, Holder GE, Seeliger MW, Yamamoto S; International Society for Clinical Electrophysiology of Vision. Standard for clinical electroretinography (2004 update). Doc Ophthalmol 2004;108:107-114
23. Anderson PJ, Watts H, Hille C, et al. Glial and endothelial blood-retinal barrier responses to amyloid-beta in the neural retina of the rat. Clin Ophthalmol 2008;2:801-816
24. Narayan SB, Ditewig-Meyers G, Graham KS, Scott R, Bennett MJ. Measurement of plasma amino acids by Ultraperformance Liquid Chromatography. Clin Chem Lab Med 2011;49:1177-1185
25. Tian G, Sol ER, Xu Y, Shuai H, Tengholm A. Impaired cAMP generation contributes to defective glucose-stimulated insulin secretion after long-term exposure to palmitate. Diabetes 2015;64:904-915
26. Park S, Dong X, Fisher TL, et al. Exendin-4 uses Irs2 signaling to mediate pancreatic beta cell growth and function. J Biol Chem 2006;281:1159-1168
27. Challa TD, Beaton N, Arnold M, Rudofsky G, Langhans W, Wolfrum C. Regulation of adipocyte formation by GLP-1/GLP-1R signaling. J Biol Chem 2012; 287:6421-6430
28. Hölscher C. Central effects of GLP-1: new opportunities for treatments of neurodegenerative diseases. J Endocrinol 2014;221:T31-T41
29. De Felice FG, Ferreira ST. Inflammation, defective insulin signaling, and mitochondrial dysfunction as common molecular denominators connecting type 2 diabetes to Alzheimer disease. Diabetes 2014;63:2262-2272
30. Bassil F, Fernagut PO, Bezard E, Meissner WG. Insulin, IGF-1 and GLP-1 signaling in neurodegenerative disorders: targets for disease modification? Prog Neurobiol 2014;118:1-18
31. Yarchoan M, Arnold SE. Repurposing diabetes drugs for brain insulin resistance in Alzheimer disease. Diabetes 2014;63:2253-2261
32. Bogdanov P, Hernández C, Corraliza L, Carvalho AR, Simó R. Effect of fe-nofibrate on retinal neurodegeneration in an experimental model of type 2 diabetes. Acta Diabetol 2015;52:113-122
33. Chou JC, Rollins SD, Ye M, Batlle D, Fawzi AA. Endothelin receptor-A antagonist attenuates retinal vascular and neuroretinal pathology in diabetic mice. Invest Ophthalmol Vis Sci 2014;55:2516-2525
34. Zhang SY, Li BY, Li XL, et al. Effects of phlorizin on diabetic retinopathy according to isobaric tags for relative and absolute quantification-based pro-teomics in db/db mice. Mol Vis 2013;19:812-821
35. Bomfim TR, Forny-Germano L, Sathler LB, et al. An anti-diabetes agent protects the mouse brain from defective insulin signaling caused by Alzheimer's disease- associated Ab oligomers. J Clin Invest 2012;122:1339-1353
36. Barber AJ, Nakamura M, Wolpert EB, et al. Insulin rescues retinal neurons from apoptosis by a phosphatidylinositol 3-kinase/Akt-mediated mechanism that reduces the activation of caspase-3. J Biol Chem 2001;276:32814-32821
37. Reiter CE, Wu X, Sandirasegarane L, et al. Diabetes reduces basal retinal insulin receptor signaling: reversal with systemic and local insulin. Diabetes 2006;55:1148-1156
38. Vuong L, Conley SM, Al-Ubaidi MR. Expression and role of p53 in the retina. Invest Ophthalmol Vis Sci 2012;53:1362-1371
39. Abu El-Asrar AM, Desmet S, Meersschaert A, Dralands L, Missotten L, Geboes K. Expression of the inducible isoform of nitric oxide synthase in the retinas of human subjects with diabetes mellitus. Am J Ophthalmol 2001;132: 551-556
40. Pouliot M, Talbot S, Sénécal J, Dotigny F, Vaucher E, Couture R. Ocular application of the kinin B1 receptor antagonist LF22-0542 inhibits retinal inflammation and oxidative stress in streptozotocin-diabetic rats. PLoS One 2012; 7:e33864
41. Rosales MA, Silva KC, Duarte DA, et al. S-nitrosoglutathione inhibits in-ducible nitric oxide synthase upregulation by redox posttranslational modification in experimental diabetic retinopathy. Invest Ophthalmol Vis Sci 2014;55:2921-2932
42. Rauen T, Rothstein JD, Wässle H. Differential expression of three glutamate transporter subtypes in the rat retina. Cell Tissue Res 1996;286:325-336
43. Sarthy VP, Pignataro L, Pannicke T, et al. Glutamate transport by retinal Muller cells in glutamate/aspartate transporter-knockout mice. Glia 2005;49:184-196
44. Hernández C, García-Ramírez M, Corraliza L, et al Topical administration of somatostatin prevents retinal neurodegeneration in experimental diabetes. Diabetes 2013;62:2569-2578
45. Wang L, Deng QQ, Wu XH, Yu J, Yang XL, Zhong YM. Upregulation of glutamate-aspartate transporter by glial cell line-derived neurotrophic factor ameliorates cell apoptosis in neural retina in streptozotocin-induced diabetic rats. CNS Neurosci Ther 2013;19:945-953